PMID- 19587067
OWN - NLM
STAT- MEDLINE
DCOM- 20091001
LR  - 20161125
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
VI  - 64
IP  - 3
DP  - 2009 Sep
TI  - BSAC standardized disc susceptibility testing method (version 8).
PG  - 454-89
LID - 10.1093/jac/dkp244 [doi]
AB  - There have been considerable changes to the format of the recommendations since 
      the previous version (version 7). The majority of the footnotes to the tables 
      have been removed and the notations added to the end column; it is hoped that 
      this change will avoid confusion in interpretation. Antibiotics have been 
      separated into groups, e.g. beta-lactams, aminoglycosides, etc. Recommendations 
      for urinary tract infections (UTIs) have been removed for most agents except for 
      those that are administered solely for the treatment of uncomplicated UTIs or 
      where there are limited recommendations for specific organisms, e.g. 
      trimethoprim. For agents that previously had dual recommendations, systemic 
      recommendations remain and the intermediate category can be used for 
      interpretation for UTIs because intermediate susceptibility infers that the 
      infection may respond as the agent is concentrated at the site of infection. This 
      change will also avoid errors in interpretation when an organism is isolated from 
      multiple sites, e.g. blood and urine. The changes that have been made to version 
      7 are as follows: MIC and zone diameter breakpoints (BPs) for trimethoprim, 
      fosfomycin and nitrofurantoin for UTIs (Table 7); MIC and zone diameter 
      breakpoints (BPs) for doripenem (Tables 7-9); colistin MIC BPs for Pseudomonas 
      spp. (Table 9), co-trimoxazole MIC BPs for Stenotrophomonas maltophilia (Table 
      10); staphylococci MIC and zone diameter BPs for clarithromycin, clindamycin, 
      erythromycin, quinupristin/dalfopristin, trimethoprim UTI, nitrofurantoin UTI and 
      rifampicin (Table 11); Streptococcus pneumoniae MIC and zone diameter BPs for 
      azithromycin, clarithromycin, erythromycin, co-trimoxazole, linezolid, rifampicin 
      and telithromycin (Table 12); addition of streptomycin recommendations for 
      enterococci (Table 13); enterococcal MIC and zone diameter BPs for 
      quinupristin/dalfopristin, nitrofurantoin UTI and trimethoprim UTI (Table 13); 
      beta-haemolytic streptococci MIC and zone diameter BPs for azithromycin, 
      clarithromycin, erythromycin and telithromycin (Table 15); clarithromycin and 
      erythromycin MIC and zone diameter BPs for Moraxella catarrhalis (Table 16); 
      azithromycin MIC BPs for Neisseria gonorrhoeae (Table 17); chloramphenicol and 
      rifampicin MIC BPs for Neisseria meningitidis (Table 18); azithromycin MIC BPs 
      for Haemophilus influenzae (Table 19); MIC BPs for metronidazole for Bacteroides 
      fragilis, Bacteroides thetaiotaomicron and Clostridium perfringens (Tables 23-25, 
      respectively); susceptibility testing of Listeria spp. (Appendix 3); the 
      acceptable range for ATCC 25923 to a 10 microg tobramycin disc (Table 26).
FAU - Andrews, J M
AU  - Andrews JM
AD  - Department of Microbiology, Sandwell and West Birmingham NHS Trust, City 
      Hospital, Birmingham B18 7QH, UK. jenny.andrews@swbh.nhs.uk
CN  - BSAC Working Party on Susceptibility Testing
LA  - eng
PT  - Journal Article
PT  - Practice Guideline
DEP - 20090708
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Bacteria/*drug effects
MH  - Humans
MH  - Microbial Sensitivity Tests/*standards
MH  - United Kingdom
EDAT- 2009/07/10 09:00
MHDA- 2009/10/02 06:00
CRDT- 2009/07/10 09:00
PHST- 2009/07/10 09:00 [entrez]
PHST- 2009/07/10 09:00 [pubmed]
PHST- 2009/10/02 06:00 [medline]
AID - dkp244 [pii]
AID - 10.1093/jac/dkp244 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2009 Sep;64(3):454-89. doi: 10.1093/jac/dkp244. Epub 2009 
      Jul 8.